Does tesamorelin build muscle? The honest answer is that it may move a lean-mass number, but it has not been shown to make healthy people more muscular or stronger. In two large trials, adults with HIV-related changes in fat distribution gained a little lean mass over 26 weeks. The trials were designed around deep abdominal fat, not bodybuilding, and they did not test strength.

That is the gap behind almost every confident claim online: lean mass, muscle size and useful strength are three different outcomes.

Does tesamorelin build muscle in the phase 3 data?

The phase 3 trials, meaning the large late-stage studies used to evaluate a medicine, enrolled 806 adults taking HIV treatment who had excess abdominal fat. Their main outcome was visceral adipose tissue, the fat packed around internal organs. Muscle growth was not the main question.

At week 26, the current Egrifta WR label reports that lean mass rose by 1.3 kg in one tesamorelin study and 1.2 kg in the other. The matching placebo groups changed by -0.2 kg and -0.03 kg. The 2010 pooled analysis by Falutz and colleagues confirms the population, trial design and 26-week timeline; the FDA prescribing information gives the study-by-study lean-mass figures.

Those are real measurements. They still do not tell us that a healthy lifter would add the same amount, that the change was all skeletal muscle, or that anyone became stronger.

Why lean mass is not the same as new muscle

A DXA scan separates fat mass, lean soft tissue, and bone mineral; its lean-soft-tissue figure includes muscle, water, organs, and other nonbone tissue, so it does not directly measure skeletal muscle. It includes muscle, but also water, organs and other nonfat tissue. DXA, a low-dose X-ray scan used for body composition, estimates lean tissue rather than directly measuring muscle fibers. A clinical review of these methods makes that limit explicit: DXA does not directly measure muscle mass.

That matters here because tesamorelin raises growth hormone and can cause fluid retention. A higher lean-mass reading can therefore contain some water. Hypertrophy, the enlargement of muscle fibers, needs more direct imaging, and a useful muscle claim also needs a strength or physical-function test. The pivotal trials supplied neither.

A muscle-specific analysis found a small structural signal

Researchers later re-read abdominal CT scans from the phase 3 program. CT is cross-sectional X-ray imaging that can estimate a muscle's area and how much fat sits inside it. This 2019 exploratory analysis included 193 tesamorelin responders and 148 placebo participants.

The analysis found small increases in the area of the rectus and psoas muscles after 26 weeks: 0.44 and 0.46 square centimeters in adjusted comparisons. It also found less fat within several trunk muscles.

That is closer to muscle tissue than a whole-body lean-mass number, but the limits are important. The tesamorelin group was restricted to people who had already responded with at least an 8% drop in visceral fat, most participants were men, and the study did not show whether they lifted more weight or functioned better. It is a clue, not a bodybuilding result.

Tesamorelin is a GHRH analogue, a lab-made version of the body's signal that tells the pituitary gland to release growth hormone. That release can raise IGF-1, a growth signal made mainly in the liver. CJC-1295 with ipamorelin reaches the same broad hormone pathway through two signals, but evidence from one compound cannot be borrowed for another.

Our broader guide to peptides and muscle growth separates hormone changes from strength outcomes, while the sermorelin muscle-growth guide looks at another GHRH analogue. In each case, a rise in IGF-1 shows that the signal worked. It does not, by itself, show that new functional muscle appeared.

The fresh 2026 evidence still stops short of proof

As of September 9, 2026, the day this article was written, a meta-analysis published July 31, 2026 pooled four randomized trials involving 909 people with HIV and lipodystrophy. A meta-analysis combines results from earlier trials. It estimated that tesamorelin increased lean mass by an average of 1.42 kg versus placebo. That sharper estimate still comes from the same narrow clinical setting; it is not new evidence in healthy lifters.

A second July publication shows what remains unanswered. The TRIUMPH trial protocol, published July 8, 2026, describes a study of 100 sedentary adults ages 50 to 80 living with HIV who are frail or at risk for frailty. Tesamorelin plus exercise will be compared with placebo plus exercise using chair stands, leg-press strength, walking time and muscle imaging. It is a protocol, so it reports a plan, not results.

Why a provider would not prescribe it just for muscle

The labeled purpose of Egrifta WR is reducing excess abdominal fat in adults with HIV and lipodystrophy. Its label does not include muscle building, and it says the medicine is weight-neutral rather than a weight-loss treatment. A provider would not reasonably turn the phase 3 lean-mass finding into a prescription for bodybuilding.

Through Promise, tesamorelin is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. A licensed provider may still prescribe a compounded formulation; that decision is between the patient and doctor.

The growth pathway also needs medical context. The label warns about elevated IGF-1, fluid retention and changes in glucose control, and it lists active malignancy, pregnancy and disruption of the pituitary pathway among the reasons branded tesamorelin should not be used. At Promise, a licensed provider reviews every request, and not everyone qualifies.

If muscle is the real goal, measure muscle

A lean-mass scan can be one data point. It cannot replace a repeatable strength test, consistent training records or imaging that actually separates muscle from other lean tissue. The outcome should match the question.

For someone considering tesamorelin for an appropriate medical reason, the useful conversation is about that reason, the evidence in a comparable population and the measurements that would show whether the plan is doing what it is meant to do. A promise of muscle from an IGF-1 rise alone skips the part the research has not answered.